Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Approval of Novavax vaccine targeting JN.1 variant comes days after mRNA coronavirus vaccines from Pfizer-BioNTech and Moderna hit shelves.

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022.

RFK Jr. recently made major cuts to mRNA vaccine development research, questioning their safety. Should you still get the ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

Novavax uses a protein-based vaccine strategy, which means people getting the vaccine receive a protein made by the virus that their body’s immune systems then see as foreign and mount responses ...

L ONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...

The Novavax vaccine, which originally showed effectiveness in a nearly 30,000-person clinical trial, is still being sold under emergency use authorization in the U.S.

Novavax’s updated COVID-19 vaccine is also authorized in the U.S. and the European Union, and is under review in other markets. The trade name Nuvaxovid has not been approved by the U.S. Food ...

WASHINGTON — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.

Since the FDA greenlighted Novavax last month, clinical studies claiming less fevers and fatigue have driven people with long COVID and chronic fatigue syndrome to seek out the protein-based vaccine.